血小板来源PD-L1在肿瘤血行转移中的免疫抑制效应及其靶向治疗策略OA
Immunosuppressive effects and targeted therapeutic strategies of platelet-derived PD-L1 in hematogenous tumor metastasis
血小板是血液中仅次于红细胞的细胞成分,传统上被认为主要是参与止血与血栓形成.血小板表面表达的程序性死亡配体1(PD-L1),可直接抑制T细胞功能;此外,血小板还能通过包裹循环肿瘤细胞(CTCs)形成物理屏障,协同放大免疫抑制信号,构成肿瘤血行转移中的移动免疫屏障.本综述系统总结了血小板PD-L1(pPD-L1)的来源与调控机制,提出pPD-L1介导免疫逃逸的三重抑制模型;继而揭示了pPD-L1作为液体活检标志物,在逆转免疫检查点抑制剂(ICIs)耐药、抑制肿瘤血行转移方面的重要地位,为靶向pPD-L1的精准治疗提供理论依据.
Platelets are the second most abundant cellular component in blood after erythrocytes and have traditionally been recognized primarily for their roles in hemostasis and thrombosis.The expression of programmed death-ligand 1(PD-L1)on the platelet surface enables direct inhibition of T cell function.Moreover,platelets can form a physical barrier by surrounding circulating tumor cells(CTCs),thereby amplifying immunosuppressive sig-nals synergistically and establishing a mobile immune barrier during hematogenous tumor metastasis.This review systematically summarizes the origin and regulatory mechanisms of platelet PD-L1(pPD-L1)and proposes a triple-inhibition model of immune evasion mediated by pPD-L1.Furthermore,it highlights the critical role of pPD-L1 as a liquid biopsy biomarker in reversing resistance to immune checkpoint inhibitors(ICIs)and suppressing hematog-enous tumor metastasis,providing a theoretical basis for precision therapies targeting pPD-L1.
姜佳宬;马洁;朱伟
江苏大学 临床医学与医学检验学院(江苏镇江 212013)||丹阳市人民医院检验科(江苏丹阳 212300)江苏大学 基础医学与公共卫生学院(江苏镇江 212013)江苏大学 临床医学与医学检验学院(江苏镇江 212013)
医药卫生
血小板程序性死亡配体1免疫逃逸血行转移免疫检查点抑制剂抗血小板治疗
plateletsprogrammed death-ligand 1immune evasionhematogenous metastasisimmune checkpoint inhibitors(ICIs)antiplatelet therapy
《实用医学杂志》 2026 (15)
2722-2729,8
国家自然科学基金资助项目(编号:32270964)
评论